

Index

A

- AA. *See* Arachidonic acid
- ACD-1, 367
- ACE. *See* Angiotensin-converting enzyme
- Actin
- cytoskeleton role in myelination, 285–287
 - myelination effects on cytoskeleton and transport, 287–299
- AD. *See* Alzheimer's disease
- ADAM17. *See* TACE
- ADAM22, myelination role, 280
- Adrenoleukodystrophy, 412
- AFF-1, 368
- Akt, myelination role, 282–284
- Alexander disease, 413, 460
- α -Synuclein, astrocyte effects of mutations, 464
- ALR-1, 362
- ALS. *See* Amyotrophic lateral sclerosis
- Alzheimer's disease (AD)
- astrocytes
 - amyloid- β effects on astrocytes, 461–462
 - functional hyperemia, 43, 45
 - reactive astrocytes, 461
 - blood–brain barrier pathology, 99
 - microglia dysfunction, 338–340
- Ammonia, astrocyte waste recycling, 55–56
- AMPA receptors
- astrocyte regulation of synapse function, 26–27
 - oligodendrocyte progenitor cells, 153–155
- Amyloid- β
- astrocyte effects, 461–462
 - astroglial regulation, 111
 - clearance, 339
 - microglia interactions, 340
- Amyotrophic lateral sclerosis (ALS)
- astrocytes
 - dysfunction, 31, 115, 466–467
 - neurotoxicity mechanisms, 467–469
 - overview, 465–466
- Angiopoietin, blood–brain barrier regulation, 93
- Angiotensin-converting enzyme (ACE), blood–brain barrier regulation, 93
- AnkG, node of Ranvier assembly regulation, 226
- ANLS. *See* Astrocyte–neuron lactate shuttle
- AP2 α , Schwann cell precursor function, 210
- APOE. *See* Apolipoprotein E
- Apolipoprotein E (APOE), polymorphisms, 116
- AQP4. *See* Aquaporin-4
- Aquaporin-4 (AQP4), autoantibodies, 116
- Arachidonic acid (AA), neurovascular coupling mediation, 38–40
- Arp2/3, myelination role, 286
- Ascl1, oligodendrocytes, 174
- Ascorbic acid, astrocyte waste recycling, 55–56
- Astrocyte
- blood–brain barrier regulation. *See* Blood–brain barrier
 - calcium signaling. *See* Calcium signaling, astrocytes
 - cerebral blood flow regulation. *See* Cerebral blood flow
 - development. *See* Ventricular–subventricular zone diseases
 - Alzheimer's disease
 - amyloid- β effects on astrocytes, 461–462
 - reactive astrocytes, 461
 - amyotrophic lateral sclerosis
 - astrocyte dysfunction, 466–467
 - neurotoxicity mechanisms, 467–469
 - overview, 465–466
 - Huntington's disease
 - huntingtin mutation effects on astrocytes, 462
 - neurotoxicity mechanisms, 462–463
 - loss of function versus toxic function, 460
 - neurotoxicity versus neuroprotection in reactive gliosis, 460–461
 - Parkinson's disease
 - neurotoxicity mechanisms, 463–465
 - overview, 463
 - prospects for study, 469
 - signaling dysfunction in disease, 468
 - Drosophila* central nervous system glia
 - growth, 350–351
 - morphology, 350–351
 - neural circuit function and behavior roles, 353–354
 - synapse pruning and formation, 351–353
 - fish radial glia relationship to astrocytes, 384–385
 - functional overview, 459
 - glioma origins, 450–451
 - gliosis. *See* Astroglial gliosis
 - heterogeneity
 - embryonic pattern formation in spinal cord, 8
 - morphological and molecular heterogeneity, 7–8
 - overview, 7
 - metabolism
 - gliosis, 58
 - glucose transporters, 53
 - glutamate recycling, 54
 - Krebs cycle intermediates, 54–55
 - measurement in single cells, 56–57
 - overview, 49–51
 - pathways and compartments, 52–56
 - prospects for study, 57–59
 - signaling, 58
 - waste recycling, 55–56

Index

Astrocyte (*Continued*)

- morphology and role as interface cells, 51–52
- neurite regeneration failure, 433
- synapse regulation. *See* Synapse

Astrocyte–neuron lactate shuttle (ANLS), 53–54

Astrogliosis

- astrocyte-mediated neuronal dysfunction/
degeneration, 117–118
- beneficial functions, 113–114
- classification
 - mild to moderate, 110
 - severe diffuse, 110
 - severe with compact scar formation, 110
- continuum of responses, 108–110
- effector molecules released, 113
- gene defects
 - mutations, 115–116
 - polymorphisms, 116
- heterogeneity, 111
- inflammation in central nervous system, 116–117
- metabolic demands, 58
- multicellular response to central nervous system
insult, 108
- overview, 107–108
- pathophysiology, 114–115
- peripheral infection and cytotoxicity, 117–118
- regulators, 111–113
- therapeutic targeting, 118–119

ATP

- perisynaptic Schwann cell at neuromuscular junction
neuromodulation, 249
- vascular basal tone regulation by astrocytes, 42–43
- zebrafish microglia function, 387–388

Atp6v0a1, 387

Autism spectrum disorder, microglia dysfunction, 323–324

AXL, astrocyte regulation of synapse elimination, 29

Axon regeneration

- astrocytes in failure, 433
- glial scar, 429–431
- macrophages in injured central nervous system
 - functions, 435–436
 - origins, 433–435
 - therapeutic targeting, 436–439
- myelin-associated growth inhibitors
 - chondroitin sulfate proteoglycans, 426–428,
430–431
 - developmental plasticity inhibition, 427–428
 - ephrins, 426
 - myelin-associated glycoprotein, 426–427
 - neuroglial-2-proteoglycan, 431–433
 - Nogo-A, 426–427, 429
 - oligodendrocyte/myelin glycoprotein,
426–427
 - Rho-associated protein kinase, 427–428
 - semaphorins, 426
 - suppression in therapy, 428–429
 - neuroglial-2-proteoglycan, 431–433
- oligodendrocyte progenitor cells and lesion core in
failure, 431–433
- overview, 425–426
- prospects for study, 439

B

- BACE, neuregulin 1 processing, 280
- Batten disease, 413
- BBB. *See* Blood–brain barrier
- BCRP, blood–brain barrier, 89
- Behavior
 - Drosophila* astrocyte studies, 353–354
 - microglia modulation
 - healthy central nervous system, 324–325
 - neuropsychiatric disorders, 323–324
- β -Catenin
 - blood–brain barrier, 91–92
 - oligodendrocyte development role, 170–171
 - zebrafish oligodendrocytes, 381
- Blood–brain barrier (BBB)
 - astrocyte function overview, 86–87
 - basement membrane, 86
 - capillary classes, 83–84
 - cell types
 - endothelial cells, 84–85
 - immune cells, 87
 - pericytes, 85–86
 - endothelial cell molecules
 - leukocyte adhesion molecules, 90–91
 - tight junctions, 88–89
 - transcytosis, 90
 - transporters, 89–90
 - pathology
 - Alzheimer's disease, 99
 - multiple sclerosis, 95–97
 - neuromyelitis optica, 95, 97
 - stroke, 97–99
 - prospects for study, 99–100
 - regulation
 - astrocytes, 93–94
 - barrier properties during angiogenesis, 91–92
 - pericytes, 92
 - signaling event conversion, 94–95
- BMP. *See* Bone morphogenetic protein
- Bone marrow, microglia origins, 305–306
- Bone morphogenetic protein (BMP)
 - embryonic pattern formation in spinal cord, 8
 - neural stem cell patterning during embryonic
development, 2
- Brg1, oligodendrocyte regulation, 177–178

C

- Clq, astrocyte regulation of synapse elimination, 28
- Caenorhabditis elegans* glia
 - neurite extension, 369–370
 - overview, 362
 - prospects for study, 371–372
 - sensory compartment roles
 - function, 365–367
 - morphogenesis, 364–365
 - sensory plasticity, 367–369
 - specification, 362–364
 - synapse
 - functions, 371
 - synaptogenesis, 370–371

- Calcium signaling, astrocytes
 - activation techniques, 74–76
 - brain studies in living mice, 73–74
 - calcium-dependent potassium uptake, 128–129
 - gliotransmitter release, 128–129
 - measurement
 - genetically encoded calcium indicators, 68–70
 - indicator dyes, 66–68
 - neural plasticity studies in vivo, 129–131
 - neuromodulator mediation, 130–131
 - neuron mediation, 71–72, 123–126
 - overview, 65–66
 - prospects for study, 77–78, 133–135
 - signal types
 - intrinsic fluctuations, 70
 - transmembrane signals and spotty microdomains, 70–71
 - waves, 70, 72–73
 - sleep, arousal, and vigilance studies, 132–133
 - cAMP
 - Gpr126 signaling, 378
 - myelination role, 283
 - Canavan's disease, 413
 - CBF. *See* Cerebral blood flow
 - CCR2, 339
 - CD11b, 316–319
 - CD33, 341
 - Cdc42, myelination role, 286
 - Central nervous system (CNS)
 - behavior modulation by microglia
 - healthy central nervous system, 324–325
 - neuropsychiatric disorders, 323–324
 - Drosophila*. *See* *Drosophila* central nervous system glia
 - microglia–synapse interactions
 - activity-dependent interactions, 319–321
 - synapse maturation and function role, 322–323
 - synaptic pruning, 321–322
 - regeneration. *See* Axon regeneration
 - spatial patterning
 - cell survival, proliferation, and differentiation regulation, 318
 - programmed cell death, 314–318
 - Cerebral blood flow (CBF)
 - capillary regulation, 41–42
 - functional hyperemia
 - history of study, 36
 - pathology, 43–44
 - neurovascular coupling
 - astrocyte-mediated neurovascular coupling
 - arachidonic acid, 38–40
 - potassium, 36, 40–41
 - overview, 36–38
 - regulation overview, 35–36
 - vascular basal tone regulation by astrocytes, 42–43
 - Channel; rhodopsin 2 (ChR2), 353–354
 - CHD4, oligodendrocyte regulation, 1788
 - CHE-14, 368
 - Chondroitin sulfate proteoglycans (CSPGs), neurite
 - regeneration inhibition, 426–428, 430–431
 - ChR2. *See* Channel; rhodopsin 2
 - Chronic inflammatory demyelinating polyneuropathy (CIDP), cell adhesion molecule autoantibodies, 230
 - CIDP. *See* Chronic inflammatory demyelinating polyneuropathy
 - c-Jun, Schwann cell repair phenotype control and maintenance, 215–216
 - Claudins, blood–brain barrier, 88–89, 92
 - CNP1
 - myelin assembly, 196
 - oligodendrocyte metabolism, 197–198
 - CNS. *See* Central nervous system
 - Colony-stimulating factor (CSF), microglia
 - development role, 303
 - Complement
 - astrocyte regulation of synapse elimination, 28–29
 - synaptic pruning, 321–322
 - CrKII, astrocyte regulation of synapse elimination, 28–30
 - CSE. *See* Colony-stimulating factor
 - Csflr, 386–387
 - CSPGs. *See* Chondroitin sulfate proteoglycans
 - CX3CR1
 - central nervous system function, 335–336
 - central nervous system microglia, 318–319, 322–324, 332
 - history of study, 333–335
 - learning-dependent synapse remodeling role, 336–337
 - pathology, 337–339
 - signaling and microglia role in neurodevelopment, 336
 - transgenic mice, 336
 - Cxcl13, 340
- ## D
- DAF-6, 364–365, 368
 - DAP12, 316–317
 - DEG, 367
 - DEG-1, 367
 - DELM-1, 367
 - DELM-2, 367
 - Desert Hedgehog (DHH), Schwann cell synthesis
 - in perineurium, 266–267
 - DEX-1, 369
 - DHH. *See* Desert Hedgehog
 - Diabetic retinopathy, astrocytes and functional hyperemia, 43–44
 - Dicer
 - astroglial regulation, 112
 - oligodendrocyte regulation, 178
 - DJ-1, astrocyte effects of mutations, 464
 - Dlg, 275
 - DNA methylation. *See* Epigenetics
 - DOCK180, astrocyte regulation of synapse elimination, 28–29
 - Drosophila* central nervous system glia
 - astrocyte
 - growth, 350–351
 - morphology, 350–351
 - neural circuit function and behavior roles, 353–354
 - synapse pruning and formation, 351–353
 - cortex glia
 - development, 356
 - morphology, 356–357

Index

Drosophila central nervous system glia (Continued)

- ensheathing glia
 - injury response, 354–356
 - morphology, 354
- glial subtypes associated with neurons, 349–350
- histology, 348
- prospects for study, 357–358

Drp2. *See* Dystrophin-related protein 2

DYF-7, 369

Dystrophin-related protein 2 (Drp2), 273

E

EC. *See* Endothelial cell

EEAT1, 353

EEAT2, 467

EGF. *See* Epidermal growth factor

ELMO, astrocyte regulation of synapse elimination, 28–30

Endothelial cell (EC), blood–brain barrier

- functional overview, 84–85
- leukocyte adhesion molecules, 90–91
- tight junctions, 88–89
- transcytosis, 90
- transporters, 89–90

Ephrins

- neurite regeneration inhibition, 426
- synapse–astrocyte interactions, 20

Epidermal growth factor (EGF), oligodendrocyte development role, 146

Epigenetics

- myelination regulation, 277
- oligodendrocyte regulation
 - chromatin remodeling complexes, 177–178
 - DNA methylation, 181–182
 - histone deacetylases, 175–177
 - overview, 174–175

ErbB

- myelination role, 279–280
- zebrafish oligodendrocytes, 383

ERK. *See* Extracellular signal-regulated kinase

Extracellular signal-regulated kinase (ERK), Schwann cell repair phenotype control and maintenance, 215

F

Fbxw7, 379

FGF. *See* Fibroblast growth factor

Fibroblast growth factor (FGF)

- oligodendrocyte progenitor cell fate switching, 144
- oligodendrocyte development role, 146, 169
- glial scar, 430
- remyelination role, 401
- zebrafish radial glia signaling, 385

FIG-1, 366–367

Fractalkine

- receptor. *See* CX3CR1
- history of study, 333–335
- central nervous system function, 335–336

Fragile X syndrome, astrocyte dysfunction, 31

Functional hyperemia. *See* Cerebral blood flow

Fyn, 383

Fzd4, blood–brain barrier, 92

G

GABA receptors

- astrocyte regulation of synapse function, 26

Drosophila central nervous system glia, 353

Gabapentin, thrombospondin receptor binding, 22–23

GFAP. *See* Glial fibrillary acidic protein

Gli, blood–brain barrier, 91

Glial fibrillary acidic protein (GFAP)

- adult B1 cell marker, 4
- astrogliosis response, 109, 111
- gene mutations, 115
- glial scar, 430
- mutations, 460
- overexpression and pathology, 117

Glial scar. *See* Axon regeneration

Glioma

origins

- astrocyte, 450–451
- neural stem cell, 449–450, 454–455
- oligodendrocyte precursor cell, 451–452
- techniques for study, 448–449

overview, 447–448

prospects for study, 452–455

Glucose transporters (GLUTs)

- astrocytes, 53
- blood–brain barrier, 90
- oligodendrocytes, 198

Glutamate, recycling in astrocytes, 53

Glutathione (GSH), astrocyte waste recycling, 55

GLUTs. *See* Glucose transporters

Gpr126

- myelination role, 281
- zebrafish Schwann cells, 376–379

GSH. *See* Glutathione

Guillain–Barré syndrome (GBS), cell adhesion molecule autoantibodies, 230

H

HD. *See* Huntington's disease

HDAC. *See* Histone deacetylase

Heartless, 351, 356

Hepatic encephalopathy, 460

Hes5, oligodendrocyte development role, 170–171

20-HETE, vascular basal tone regulation by astrocytes, 42, 45

Hevin, astrocyte regulation of synapse formation, 23–24

Histone deacetylase (HDAC)

- myelination regulation, 276
- oligodendrocyte regulation, 175–177

Huntington's disease (HD)

- astrocytes
 - dysfunction, 115
 - huntingtin mutation effects on astrocytes, 462
 - neurotoxicity mechanisms, 462–463
 - nuclear factor- κ B activation, 461

I

Id, oligodendrocyte regulation, 169–171

IDH1. *See* Isocitrate dehydrogenase 1

- IGF-1. *See* Insulin-like growth factor-1
- Induced pluripotent stem cell (iPSC), remyelination therapy, 409, 411–412
- Insulin-like growth factor-1 (IGF-1), 318–319
- Internode. *See* Myelinated axons
- iPSC. *See* Induced pluripotent stem cell
- IRF-8, 304, 386
- Isocitrate dehydrogenase 1 (IDH1), glioma mutations, 447–448, 453
- J**
- Jacop, blood–brain barrier, 89
- JAM4, blood–brain barrier, 89
- Juxtaparanode. *See* Myelinated axons
- K**
- Kif1b, 382
- Krabbe's disease, 412
- KRAS, glioma mutations, 449, 451
- Krox20, myelination regulation, 276–277
- L**
- Lactate dehydrogenase (LDH), 55
- Laminin
myelination role, 280–281
Schwann cell proliferation role, 212
- LAMs. *See* Leukocyte adhesion molecules
- Lck, myelination role, 286
- LDH. *See* Lactate dehydrogenase
- Lef1, blood–brain barrier, 91
- Leukocyte adhesion molecules (LAMs), blood–brain barrier, 90–91
- Lgi4, myelination role, 280
- Lgl, 275
- LIGHT, 467
- LIN-26, 362
- LINGO-1, 401, 406
- LIT-1, 364–365
- LKB1, 199
- Long-term depression (LTD), astrocyte regulation of synapse function, 27
- Long-term potentiation (LTP)
astrocyte mechanisms, 129
astrocyte regulation of synapse function, 27
- LRP1, blood–brain barrier, 90, 99
- LTD. *See* Long-term depression
- LTP. *See* Long-term potentiation
- M**
- Mac-2, astrocyte regulation of synapse elimination, 30
- Macrophage
blood–brain barrier interactions, 87
development and homeostasis factors, 303–304
history of microglia studies, 298–299, 331–333
injured central nervous system
functions, 435–436
origins, 433–435
therapeutic targeting, 436–439
markers, 299
yolk sac and microglia origins, 299–303
- MAG. *See* Myelin-associated glycoprotein
- Magnetic resonance imaging (MRI), oligodendrocyte adaptive myelination in adulthood, 156–157
- Maltose-binding protein (MBP), 274
- Mammalian target of rapamycin (mTOR), myelination role, 282–283
- MAPK. *See* Mitogen-activated protein kinase
- Markers, microglia, 299
- Matrix metalloproteinases (MMPs)
Alzheimer's disease pathology, 99
multiple sclerosis pathology, 96
stroke pathology, 98
- MBP. *See* Maltose-binding protein
- MBP. *See* Myelin basic protein
- MCT. *See* Monocarboxylate transporter
- Mdr1, blood–brain barrier, 89
- MEGF10, astrocyte regulation of synapse elimination, 30
- MERTK, astrocyte regulation of synapse elimination, 29–30
- Metachromatic leukodystrophy (MLD), 413
- MicroRNA
astroglial regulation, 112–111
Caenorhabditis elegans glia and sensory plasticity, 369
oligodendrocyte development regulation, 178–181
- Mitogen-activated protein kinase (MAPK), myelination role, 282–283
- MLD. *See* Metachromatic leukodystrophy
- MLS-2, 363
- MMPs. *See* Matrix metalloproteinases
- Molecular definition, microglia, 340–341
- Monocarboxylate transporter (MCT)
astrocyte, 54
oligodendrocyte, 198
remyelination role, 400
- MPP7, blood–brain barrier, 89
- MRI. *See* Magnetic resonance imaging
- MS. *See* Multiple sclerosis
- mTOR. *See* Mammalian target of rapamycin
- Muller glia, 351
- Multiple sclerosis (MS)
blood–brain barrier pathology, 95–97
cell adhesion molecule autoantibodies, 230
microglia dysfunction, 337–338
microglia self-renewal, 306
oligodendrocyte progenitor cell density, 162
transplantation, 416–417
remyelination failure, 404–405
- Mushroom body γ neuron, 351–352
- Myelin
assembly, 193–197
functional overview, 221
neurite regeneration inhibition. *See* Axon regeneration structure, 191–193
- Myelin-associated glycoprotein (MAG), 273, 426–427
- Myelinated axons. *See also* Nodes of Ranvier
assembly regulation
cell adhesion molecules, 228
extrinsic regulators, 226–229

Index

- Myelinated axons (*Continued*)
intrinsic regulators, 226
nodal axoglial interactions
central nervous system nodes, 228–229
peripheral nervous system nodes, 227–228
composition
internodes, 225–226
juxtaparanodes, 225
nodes of Ranvier, 224–225
paranodal junctions, 225
excitable domain maintenance, 229–231
morphology of types, 221–224
- Myelination
cells. *See* Oligodendrocyte; Schwann cell
oligodendrocytes, 155–157, 193–197
remyelination. *See* Remyelination
Schwann cells
actin cytoskeleton role, 285–287
cell dedifferentiation and signaling pathway
activation, 284
epigenetics, 277
extrinsic signals
ADAM22, 280
ErbB, 279–280
Gpr126, 281
laminin, 280–281
Lgi4, 280
neuregulin 1, 277, 279–281, 283, 286
overview, 277–289
function consequences of myelination on axon,
287–288
intracellular signaling
Akt, 282–284
cAMP, 283
mammalian target of rapamycin, 282–283
mitogen-activated protein kinase, 282–283
phospholipase C, 282
overview, 271–272
peripheral nervous system myelin sheath
organization and polarity, 272–275
prospects for study, 288–289
sheath morphogenesis, 284–285
termination, 283–284
transcriptional regulation, 276–277
- Myelin basic protein (MBP)
myelin assembly, 196–197
myelin structure, 192
oligodendrocytes, 170
- Myelin regulatory factor (Myrf)
oligodendrocytes, 173–174
zebrafish oligodendrocytes, 380–381
- MyoD, 364
Myrf. *See* Myelin regulatory factor
- N**
- NCL. *See* Neuronal ceroid lipofuscinoses
Necl-2, 273
Necl-4, 273
Neimann–Pick disease, 412
Nerve growth factor (NGF)
microglia expression and cell death, 316, 319
Schwann cell survival role, 212
Neural progenitor cell (NPC), microglia regulation in
central nervous system, 317–318
Neural stem cell (NSC). *See also* Ventricular–
subventricular zone
glioma origins, 449–450, 454–455
remyelination therapy, 409, 411–412
Neuregulin 1 (NRG1)
myelination role, 277, 279–281, 283, 286
processing, 280
remyelination role, 398
Schwann cell
precursor function, 210
proliferation role, 211
- Neurite
Caenorhabditis elegans glia in extension, 369–370
regeneration. *See* Axon regeneration
Neurogenin, oligodendrocyte progenitor cell fate
switching, 143
Neuroglial-2-proteoglycan (NG2), neurite regeneration
inhibition, 431–433
Neuromuscular junction (NMJ)
organization in vertebrates, 238–240
perisynaptic Schwann cell
decoding of synaptic properties and activity, 246
maintenance of synapses, 241
plasticity of properties, 249–250
prospects for study, 250–251
regeneration and degeneration of synapses,
242–243
remodeling of synapses, 241–242
synaptic activity and plasticity modulation,
246–249
synaptic activity integration to establish synaptic
properties, 250
synaptic transmission detection, 244–246
synaptogenesis role, 240–241
- Neuromyelitis optica (NMO)
aquaporin-4 autoantibodies, 116
blood–brain barrier pathology, 95, 97
Neuronal ceroid lipofuscinoses (NCL), 412–413
Neuropilin, oligodendrocyte development role, 148
Neurovascular coupling. *See* Cerebral blood flow
NF- κ B. *See* Nuclear factor- κ B
NF1, glioma mutations, 449, 452
NF186
excitable domain maintenance, 229–230
node of Ranvier assembly regulation, 227–228
NFATc4, myelination regulation, 276
NG2. *See* Neuroglial-2-proteoglycan
NGF. *See* Nerve growth factor
Nitric oxide (NO)
astrocytes and functional hyperemia in diabetic
retinopathy, 43
stroke pathology, 98
- Nkx2.2
oligodendrocytes, 169, 172–174
perineurial glia development, 261–262
Nkx6.1, embryonic pattern formation in
spinal cord, 8
NLR. *See* NOD-like receptor

- NMDA receptors
 - oligodendrocyte progenitor cells, 153–155
 - sleep, arousal, and vigilance studies of
 - astrocytes, 132
 - stroke pathology, 98
 - NMJ. *See* Neuromuscular junction
 - NMO. *See* Neuromyelitis optica
 - NO. *See* Nitric oxide
 - NOD-like receptor (NLR), 386–387
 - Nodes of Ranvier
 - assembly regulation
 - cell adhesion molecules, 228
 - extrinsic regulators, 226–229
 - intrinsic regulators, 226
 - nodal axoglial interactions
 - central nervous system nodes, 228–229
 - peripheral nervous system nodes, 227–228
 - composition, 224–225
 - Nogo-A, neurite regeneration inhibition, 426–427, 429
 - Norrin, blood–brain barrier, 92
 - Notch
 - oligodendrocyte development role, 143, 169–169
 - Schwann cell functions
 - precursor, 210
 - proliferation, 211
 - repair phenotype control and maintenance, 216
 - zebrafish oligodendrocyte signaling, 379–380
 - NPC. *See* Neural progenitor cell
 - NRG1. *See* Neuregulin 1
 - NSC. *See* Neural stem cell
 - Nuclear factor- κ B (NF- κ B)
 - astrogliosis regulation, 113
 - Huntington's disease activation, 461
 - myelination regulation, 276
- O**
- Obsessive–compulsive disorder, microglia dysfunction, 323–324
 - Occludin, blood–brain barrier, 89
 - ODR-10, 368
 - Olig1
 - oligodendrocyte regulation, 172, 179
 - remyelination role, 401
 - zebrafish oligodendrocytes, 380–381
 - Olig2
 - embryonic pattern formation in spinal cord, 8
 - oligodendrocyte regulation, 143–144, 168–169, 171, 174, 178–179
 - zebrafish, 380
 - Oligodendrocyte. *See also* Myelination; Remyelination
 - adaptive myelination in adulthood, 155–157
 - axioglial synaptic signaling and development, 152–155
 - development
 - brain, 140–142
 - growth factors, 145–147
 - nonmammalian vertebrates, 142–143
 - progenitor cells
 - fate switching, 143–144
 - overview, 139–140, 167
 - spinal cord, 140
 - ventral versus dorsal cell functions, 144–145
 - epigenetic regulation
 - chromatin remodeling complexes, 177–178
 - DNA methylation, 181–182
 - histone deacetylases, 175–177
 - overview, 174–175
 - functions in adult central nervous system, 149–152
 - history of study, 189–191
 - maturation and myelination regulators, 172–174
 - metabolic support of axon function, 197–199
 - metabolism, 57–58
 - microRNA regulation, 178–181
 - myelin assembly, 193–197
 - population dynamics, 147–149
 - precursor cell transplantation
 - adult indications, 416
 - challenges, 414, 416–417
 - multiple sclerosis, 416–417
 - neonatal delivery, 413–415
 - pediatric indications, 412–413
 - sources, 407–412
 - progenitor cell and glioma origins, 451–452
 - synaptic signaling between neurons and oligodendrocyte progenitor cells, 151–155
 - transcription factors
 - overview, 168
 - prodifferentiation factors, 171–172
 - progenitor cell maintenance, 168–169
 - terminal differentiation regulation, 169–171
 - zebrafish
 - differentiation, 380–381
 - injury and disease studies, 383
 - myelination regulation
 - cellular regulation, 381–382
 - molecular regulation, 382–383
 - precursor cells, 380
 - specification of progenitors, 379–380
 - Oligodendrocyte/myelin glycoprotein (OMgp), neurite regeneration inhibition, 426–427
 - OMgp. *See* Oligodendrocyte/myelin glycoprotein
- P**
- Pannexin-1, 387
 - Par-3, myelin sheath organization and polarity, 274–275
 - Paranodal axoglial junction. *See* Myelinated axons
 - Parkin, astrocyte effects of mutations, 464
 - Parkinson's disease (PD)
 - astrocyte neurotoxicity mechanisms, 463–465
 - overview, 463
 - PCD. *See* Programmed cell death
 - PD. *See* Parkinson's disease
 - PDGF. *See* Platelet-derived growth factor
 - Pelizaeus–Merzbacher disease (PMD), 400, 413, 416
 - Pericyte, blood–brain barrier
 - functional overview, 85–86
 - regulation, 92

Index

- Perineurial glia
 formation from spinal motor nerve
 perineurium, 259–262
 motor nerve development
 role, 262–264
 Schwann cell interactions, 265–268
 nerve regeneration role, 264–265
 overview, 257–258
 prospects for study, 268
- Perisynaptic Schwann cell. *See* Schwann cell
- PGE2. *See* Prostaglandin E2
- Phospholipase A₂ (PLA₂), cerebral blood flow
 regulation, 40
- Phospholipase C (PLC), myelination role, 282
- PLA₂. *See* Phospholipase A₂
- Platelet-derived growth factor (PDGF)
 oligodendrocyte development role, 145, 147–148
 remyelination role, 401, 403
- PLC. *See* Phospholipase C
- PLP
 mutation and axon loss, 399–400
 myelin structure, 192
 oligodendrocytes, 171, 173–174
- PLVAP, blood–brain barrier, 92
- PMD. *See* Pelizaeus–Merzbacher disease
- PMP22, 274
- Potassium
 action potential threshold setting by extracellular
 potassium, 127–128
 calcium-dependent potassium uptake, 128–129
 extraneurovascular coupling mediation, 36, 40–41
- Pou3f, myelination regulation, 276
- Pregabalin, thrombospondin receptor binding, 22
- Programmed cell death (PCD), central nervous system
 spatial patterning, 314–318
- Prostaglandin E2 (PGE2), cerebral blood flow regulation,
 36, 39–42
- PTEN*, glioma mutations, 449–452
- PTPRZ1*, 406–407
- PU.1
 microglia development role, 303–304
 zebrafish, 386–387
- R**
- RA. *See* Retinoic acid
- Rac1
 astrocyte regulation of synapse
 elimination, 28–29
 myelination role, 286–287
- Raf, Schwann cell repair phenotype control and
 maintenance, 215
- RAM-5, 369
- RBI*, glioma mutations, 449, 451
- Remack Schwann cells, 257–258
- Remyelination
 axon protection, 399–400
 demyelination response, 399
 enhancement
 oligodendrocyte progenitor cell transplantation
 adult indications, 416
 challenges, 414, 416–417
 multiple sclerosis, 416–417
 neonatal delivery, 413–415
 pediatric indications, 412–413
 sources, 407–412
 prospects, 417
 stem cell therapy, 409, 411–412
 therapeutic targets, 405–407
 failure causes, 403–406
 mechanisms
 inflammation, 401–402
 oligodendrocyte progenitor cells
 activation, recruitment, and differentiation,
 400–401
 induction, 400
 overview, 397–399
 Schwann cells, 402–403
- Retinoic acid (RA)
 blood–brain barrier regulation, 93–94
 9-*cis*-retinoic acid and remyelination
 enhancement, 406
- Rett syndrome, astrocyte dysfunction, 31
- Rgr1, myelination regulation, 276
- Rho-associated protein kinase (ROCK), neurite
 regeneration inhibition, 427–428
- ROCK. *See* Rho-associated protein kinase
- S**
- Schizophrenia, microglia dysfunction, 323–324
- Schmidt–Lanterman incisure, 274
- Schwann cell. *See also* Myelination; Remyelination
 development
 immature cells in embryonic nerves
 proliferation drivers, 211–212
 survival regulation, 212
 precursor
 developmental potential, 208
 generation from neural crest, 209
 lineage, 205–207
 nerve fasciculation, 210–211
 phenotype, 208–209
 survival and differentiation, 209–210
 survival modulation of dorsal root ganglion and
 motoneurons, 211
 stages, 207–208
 injury response in nerve stump, 214–215
 myelination
 actin cytoskeleton role, 285–287
 cell dedifferentiation and signaling pathway
 activation, 284
 epigenetics, 277
 extrinsic signals
 ADAM22, 280
 ErbB, 279–280
 Gpr126, 281
 laminin, 280–281
 Lgi4, 280
 neuregulin 1, 277, 279–281, 283, 286
 overview, 277–289
 function consequences of myelination on axon,
 287–288

- intracellular signaling
 - Akt, 282–284
 - cAMP, 283
 - mammalian target of rapamycin, 282–283
 - mitogen-activated protein kinase, 282–283
 - phospholipase C, 282
 - overview, 271–272
 - peripheral nervous system myelin sheath
 - organization and polarity, 272–275
 - prospects for study, 288–289
 - sheath morphogenesis, 284–285
 - termination, 283–284
 - transcriptional regulation, 276–277
 - nerve damage response, 212–213
 - perineurial glia
 - interactions in motor nerve development, 265–266
 - role in differentiation, 261, 263
 - perisynaptic Schwann cell at neuromuscular junction
 - decoding of synaptic properties and activity, 246
 - maintenance of synapses, 241
 - plasticity of properties, 249–250
 - prospects for study, 250–251
 - regeneration and degeneration of synapses, 242–243
 - remodeling of synapses, 241–242
 - synaptic activity and plasticity modulation, 246–249
 - synaptic activity integration to establish synaptic properties, 250
 - synaptic transmission detection, 244–246
 - synaptogenesis role, 240–241
 - plasticity, 213–214
 - Remack Schwann cells, 257–258
 - repair phenotype control and maintenance, 215–216
 - zebrafish
 - Gpr126, 376–379
 - overview, 376
 - Self-renewal, adult microglia
 - disease, 305–306
 - homeostasis, 304–305
 - Semaphorins, neurite regeneration inhibition, 426
 - Shh. *See* Sonic hedgehog
 - Sip1. *See* Zfhx1b
 - SLI, 275
 - SOD. *See* Superoxide dismutase
 - Sonic hedgehog (Shh)
 - blood–brain barrier, 91
 - blood–brain barrier regulation, 93
 - embryonic pattern formation in spinal cord, 8
 - neural stem cell patterning during embryonic development, 2
 - oligodendrocyte progenitor cell fate switching, 143–144
 - SOX
 - myelination regulation, 276–277
 - oligodendrocyte regulation, 169–171
 - Schwann cell functions
 - repair phenotype control and maintenance, 215–216
 - survival, 266
 - SPARC
 - astrocyte regulation of synapses
 - formation, 23–24
 - function, 27
 - zebrafish oligodendrocytes, 380–381
 - STAT3, 460, 467
 - Stroke, blood–brain barrier pathology, 97–99
 - Superoxide dismutase (SOD), gene mutations, 115
 - SWI2/SNF2, oligodendrocyte regulation, 177
 - Synapse. *See also* Neuromuscular junction
 - astrocyte processes
 - ensheathment of synapses and functional domain defining, 18–19
 - segregation of neighboring synapses, 19
 - Caenorhabditis elegans* glia
 - functions, 371
 - synaptogenesis, 370–371
 - central nervous system microglia–synapse interactions
 - activity-dependent interactions, 319–321
 - synapse maturation and function role, 322–323
 - synaptic pruning, 321–322
 - Drosophila* astrocytes in pruning and formation, 351–353
 - dynamics of astrocyte interactions, 19–20
 - elimination regulation by astrocytes
 - direct role, 28–31
 - indirect role, 28
 - overview, 27–28
 - formation regulation by astrocytes
 - developmental alteration of synaptogenic cues, 23
 - SPARC, 23
 - thrombospondins, 21–23
 - function regulation by astrocytes
 - overview, 17–18, 24
 - plasticity, 27
 - postsynaptic function, 26–27
 - presynaptic function, 24–26
 - perisynaptic Schwann cell. *See* Schwann cell
 - retinal ganglion cell culture system, 20–21, 23–24
 - synaptic signaling between neurons and oligodendrocyte progenitor cells, 151–155
- ## T
- TACE (ADAM17), neuregulin 1 processing, 280
 - TAK-1, 337–338
 - TGF- β . *See* Transforming growth factor- β
 - TH. *See* Thyroid hormone
 - Thrombospondins (TSPs), astrocyte regulation
 - of synapses
 - formation, 21–23
 - function, 26–27
 - Thyroid hormone (TH), oligodendrocyte development role, 147
 - TNF- α . *See* Tumor necrosis factor- α
 - TP53, glioma mutations, 449–450, 452
 - Transferrin receptor, blood–brain barrier, 90
 - Transforming growth factor- β (TGF- β)
 - astrocyte regulation of synapse elimination, 28
 - blood–brain barrier regulation, 93

Index

Transforming growth factor- β (TGF- β) (*Continued*)

- glial scar, 430
- oligodendrocyte development role, 146
- Schwann cell regulation
 - proliferation, 211–212
 - survival, 12

TREM2, 341

TRPA1, astrocyte calcium signaling, 71

TSPs. *See* Thrombospondins

TTX-1, 368

Tumor necrosis factor- α (TNF- α), astrocyte regulation

- of synapse function, 27

TYRO3m astrocyte regulation of synapse elimination, 29

U

UNC-40, 371

UNC-6, 370–371

V

VAB-3, 363

Vascular endothelial growth factor (VEGF)

- blood–brain barrier regulation, 93
- multiple sclerosis pathology, 97
- stroke pathology, 98

VEGF. *See* Vascular endothelial growth factor

Ventricular–subventricular zone (VSV)

- adult astrocytes
 - astromere diversification, 10–11
 - neural stem cell properties, 4–5
 - regional function in sensorimotor circuit
 - regulation, 10
 - regional heterogeneity and regulation, 5–6, 11
 - temporal specification
 - neural stem cell glial lineage, 6
 - prospects for study, 11–12
 - regional astrocyte allocation from segmental progenitor template, 8–10
 - temporal patterning, 6–7
- neural stem cell heterogeneity
 - forebrain cell heterogeneity during embryonic development, 2
 - temporal heterogeneity during embryonic development, 2–4

VSV. *See* Ventricular–subventricular zone

W

Wallerian degeneration (WD), 430

WASP, 365

WD. *See* Wallerian degeneration

Wnt

- blood–brain barrier, 91
- oligodendrocyte development
 - role, 170–171

X

Xpr1, 386–387

Y

Yolk sac (YS), microglia origins, 299–303

YS. *See* Yolk sac

YY1, myelination regulation, 276

Z

Zebrafish glia

- central nervous system–peripheral nervous system boundary, 383–384

microglia

- developmental functions, 387–388
- injury response, 388
- origins and migration, 386–387
- oligodendrocyte
 - differentiation, 380–381
 - injury and disease studies, 383
 - myelination regulation
 - cellular regulation, 381–382
 - molecular regulation, 382–383
 - precursor cells, 380
 - specification of progenitors, 379–380
- overview, 375–376
- prospects for study, 388
- radial glia relationship to astrocytes, 384–385
- Schwann cell
 - Gpr126 function, 376–379
 - overview, 376

Zfhx1b (Sip1), oligodendrocyte development

- role, 171

ZO-1

- blood–brain barrier, 88–89
- stroke pathology, 97–98

Zydeco, 357